TY -的T1 -肺hyperten恶化sion and pleural effusion with bosutinib following dasatinib lung toxicity JF - European Respiratory Journal JO - Eur Respir J SP - 1517 LP - 1519 DO - 10.1183/13993003.01410-2016 VL - 48 IS - 5 AU - Riou, Marianne AU - Seferian, Andrei AU - Savale, Laurent AU - Chaumais, Marie-Camille AU - Guignabert, Christophe AU - Canuet, Matthieu AU - Magro, Pascal AU - Rea, Delphine AU - Sitbon, Olivier AU - Jaïs, Xavier AU - Humbert, Marc AU - Montani, David Y1 - 2016/11/01 UR - //www.qdcxjkg.com/content/48/5/1517.abstract N2 - Tyrosine kinase inhibitors (TKIs) targeting BCR/ABL such as imatinib, nilotinib, dasatinib, bosutinib and ponatinib have revolutionised the management of patients with chronic myeloid leukaemia (CML) [1]. Pleural effusions and pulmonary arterial hypertension (PAH) have been reported in patients treated with these agents [2–4]. These side-effects are more frequently observed with dasatinib use, with partial or complete reversibility after drug withdrawal [3]. Bosutinib is a second-generation TKI prescribed in case of intolerance or resistance to imatinib, nilotinib or dasatinib. In the present report, we describe two cases of worsening of dasatinib-induced PAH and two cases of severe pleural effusions, suggesting overlapping pulmonary toxicity of bosutinib and dasatinib.Pulmonary complications of bosutinib therapy and potential cross-intolerance with dasatinib http://ow.ly/UKWu303KGhxWe acknowledge the French pulmonary hypertension pharmacovigilance network, VIGIAPATH, supported by the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM). ER -